Siemens Healthineers Q1 profit slides on lower COVID test sales

Revenues for the fiscal first quarter came to 5.08 billion euros, down 4.5 percent on a comparable basis, which was also below consensus for 5.21 billion.

Published On 2023-02-03 08:45 GMT   |   Update On 2023-02-03 08:45 GMT
Advertisement

Berlin: Siemens Healthineers reported a 28 percent drop in quarterly operating profit due to lower sales of rapid COVID-19 antigen tests and delays at a supplier of its Varian business.

Pandemic lockdowns in China led to a drop in revenue at Healthineers' Diagnostics business by nearly a quarter as fewer COVID-19 tests were used there, the U.S.-German medical device maker said on Thursday.
Adjusted earnings before interest and tax (EBIT) for the three months through December fell to 647 million euros ($712.93 million), less than the 663 million expected by analysts, according to a consensus provided by the company.
Advertisement
Revenues for the fiscal first quarter came to 5.08 billion euros, down 4.5 percent on a comparable basis, which was also below consensus for 5.21 billion.
The company nonetheless stuck with its guidance for full-year revenue growth of -1 percent to +1 percent, or 6-8 percent growth excluding revenue from COVID-19 tests, and said it still saw adjusted basic earnings per share of 2 euros to 2.20 euros.

Read also: Siemens Healthineers to sell USD 140 million in medical equipment to Atrium Health



Tags:    
Article Source : Reuters

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News